Xianruida Medical-B (06669.HK): The results for the first half of the year are in line with expectations and awaiting overseas results
中金公司Aug 26, 2023 00:00
Xianruida Medical-B (06669.HK): Disclosing Continued Related Transactions Leading a New Paradigm for Innovative Medical Devices
中金公司Jul 26, 2023 07:42
CICC: First offer to Xianruida Medical-B (06669) “Outperform the Industry” rating with a target price of HK$23
Zhitong FinanceDec 30, 2022 11:02
Xianruida Medical-B (06669.HK): Losses in performance turned into commercialization of the profitable business
國信證券Sep 2, 2022 00:00
Xianruida Healthcare (06669.HK): The revenue structure of the pharmacy, suction, and radio frequency troika is gradually diversifying
興業證券Aug 30, 2022 16:56
Xianruida Medical-B (6669.HK): The first-mover advantage of peripheral pharmaceuticals is significant, and the research pipeline is rich, opening up space for long-term growth
中信建投證券Aug 9, 2022 20:56
Xianruida Medical-B (06669.HK): DCB drives performance growth, peripheral intervention adds a powerful tool
國信證券Apr 10, 2022 00:00
Xianruida Medical-B (06669.HK): One Tree Drug Balloon, One Big Flag
興業證券Aug 13, 2021 00:00
Xianruida Healthcare (6669.HK): IPO Report Rating: 75 Rating: Subscription
中泰國際Aug 12, 2021 00:00
No Data
No Data